Evidence map›Paper›PMID 42824698›Full record

ReviewClinical kidney journal2026

Ten tips to reduce fracture risk by non-pharmacologic interventions in CKD-associated osteoporosis.

Ditte Hansen, Hanne Skou-Jørgensen, Mehmet Kanbay, Maria Fusaro, Louise Salomo, Susanne Fleig, Stig Molsted, Jesper Ryg, Mathias Haarhaus, Pieter Evenepoel

Abstract readReview
In one paragraph

Review in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ditte HansenDepartment of Nephrology, Copenhagen University Hospital - Herlev, Copenhagen, Denmark.ORCID https://orcid.org/0000-0003-4929-7901
Hanne Skou-JørgensenDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.ORCID https://orcid.org/0000-0002-0881-2615
Mehmet KanbayDepartment of Internal Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey.ORCID https://orcid.org/0000-0002-1297-0675
Maria FusaroNational Research Council (CNR), Institute of Clinical Physiology (IFC), Pisa, Italy.ORCID https://orcid.org/0000-0001-9478-4851
Louise SalomoDepartment of Nephrology, Copenhagen University Hospital - Herlev, Copenhagen, Denmark.
Susanne FleigDepartment of Nephrology and Clinical Immunology, RWTH Aachen University Hospital, Aachen, Germany.ORCID https://orcid.org/0000-0002-2886-2222
Stig MolstedInstitute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Jesper RygInstitute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-8641-3062
Mathias HaarhausDivision of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska Universitetssjukhuset, Stockholm, Sweden.ORCID https://orcid.org/0000-0001-8274-6356
Pieter EvenepoelDepartment of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, Katholieke Universiteit Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0002-0797-4321

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD)-associated osteoporosis is present in approximately 25% of all patients with CKD. The occurrence increases as kidney function declines, with prevalences up to 75% in elderly dialysis patients. It is often undiagnosed due to the perception that limited treatment options are available for this condition. This inappropriate assumption leads to diagnostic and therapeutic nihilism. The effect-size of pharmacological interventions on bone mineral density in patients with CKD is comparable to or higher than in other forms of osteoporosis. Non-pharmacological interventions can improve bone strength and fracture risk in addition to pharmacological interventions. Importantly, they are often applicable to patients with CKD without restrictions, with some specific considerations in end-stage kidney disease. Due to the increased prevalence of modifiable risk factors for fragility fractures in CKD, non-pharmacological interventions should be provided to all patients with CKD-associated osteoporosis. We review the current literature and describe 10 tips for non-pharmacological interventions with the potential to modify fracture risk in CKD patients: appropriate intake of calcium and vitamin D, adequate nutrition and protein intake, avoidance of smoking and alcohol, medication review, reinforcement of exercise, reducing risk of home hazards, prevention of orthostatic hypotension, taking care of neuropathy and determining fall risk, as well as implementing fracture liaison services, are all actions of relevance to the patient with CKD-associated osteoporosis. As in the general population, non-pharmacological interventions should be the first option to consider when osteoporosis is diagnosed. With this paper, we suggest how this should be tailored to the patient with CKD.

Indexed as

calciumchronic renal failureCKD-MBDmineral metabolismvitamin D

Identifiers

PMID42824698
PMCPMC13627839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.